This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 07 February 2025; doi:10.1038/s41569-025-01131-4 Hypertension is the leading cause of death globally but has low rates of diagnosis and treatment.
tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension.
The buzz around artificial intelligences impact on cardiology keeps growing louder, and thats proving to be particularly true in the AI-ECG segment, with 2025 already off to a strong start from ECG startups and researchers alike. The post AI-ECGs 2025 Kickoff appeared first on Cardiac Wire. For reference, 37M people in the U.S.
Key treatable traits in COPD-associated pulmonary hypertension include hypoxemia, inflammation, and right ventricular dysfunction. In stable COPD, cardiovascular complications are a leading cause of mortality, whereas acute exacerbations can worsen heart function.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Nature Reviews Cardiology, Published online: 02 January 2025; doi:10.1038/s41569-024-01104-z Endovascular renal denervation has been approved for the treatment of hypertension.
tim.hodson Mon, 02/10/2025 - 12:43 Feb. 6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH).
tim.hodson Fri, 02/14/2025 - 14:32 Feb. tim.hodson Fri, 02/14/2025 - 14:32 Feb. The presentation,"Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction,"was deliveredby Marat Fudim, M.D., Advanced Heart Failure Cardiologist, Duke Health on Feb.
tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. The Company anticipates initiating the trial in the first quarter of 2025.
tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). Accessed February 21, 2025. Accessed March 5, 2025. Accessed February 21, 2025. 4 Approximately 6.7
In 2025, the world of healthcare is changing daily, and nowhere is this more apparent than in cardiology. In 2025, the demand for telehealth capabilities will only continue to grow, especially in managing chronic conditions like hypertension and heart disease.
Photo: American Heart Association tim.hodson Tue, 01/14/2025 - 16:05 Jan. 9, 2025 Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond, according to new research published in Hypertension , a peer-reviewed journal of the American Heart Association. Cameron, M.D,
Hypertension, Volume 82, Issue 1 , Page 72-83, January 1, 2025. BACKGROUND:Hypertension increases the risk of lymphedema in patients with comorbidities, but whether hypertension directly compromises lymph vessel (LV) function and lymph flow is unclear. Mesenteric lymph flow in vivo was 2.9-fold
Hypertension, Volume 82, Issue 1 , Page 14-25, January 1, 2025. Podocyte dysfunction, resulting from oxidative stress, dysregulated prosurvival signaling, or structural damage, can drive the development of proteinuria and glomerulosclerosis in hypertensive nephropathy.
tim.hodson Tue, 02/18/2025 - 10:08 Feb. 13, 2025 Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease. Image by Getty.
Hypertension, Volume 82, Issue 1 , Page 26-35, January 1, 2025. Hypertension management involves using blood pressure and other biometric data from connected devices and generative AI to communicate with patients and health care professionals.
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors.
It becomes effective January 1, 2025, and is expected to remain effective for up to three years. This is a major step forward in the reimbursement available for the Paradise uRDN system, creating additional financial support for hospitals and physicians to provide this novel and effective therapy to their uncontrolled hypertension patients.”
Stroke, Volume 56, Issue Suppl_1 , Page ATP282-ATP282, February 1, 2025. The main risk factor is hypertension, and blood pressure (BP) control is crucial in the primary and secondary prevention of stroke. The 2020 AHA Guideline was used to define hypertension and target BP. Statistical analysis was performed using STATA/SE 17.0
Stroke, Volume 56, Issue 1 , Page 105-112, January 1, 2025. BACKGROUND:The focus for reducing hypertension-related cardiovascular disease is the management of blood pressure. Participants were stratified by duration of recognized hypertension: normotensive (0 years), 5 years, 6 to 20 years, or 21+ years.
Stroke, Volume 56, Issue Suppl_1 , Page ADP50-ADP50, February 1, 2025. million patients with hypertension were assessed. However, patients on non-ACEI/ARBs anti-hypertensive medications had a similar risk of SAH risk compared to those not on any antihypertensives [HR:1.00(0.97-1.04), million,follow-up:6.3 years, average age 61.9,
📅 Date: Wednesday, February 5th 2025 ⏰ Time: 2 pm Irish Time 📍 Where: Online (Link provided after registration) 👉 Click here to reserve your spot now. Sign Me Up 1 The global epidemiology of hypertension. 5 Role of insulin resistance in essential hypertension. The Cholesterol Secrets Masterclass?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content